This page separates reported trial results from statistical interpretation. The numerical results presented here are restricted to the statistical analyses posted in the ClinicalTrials.gov record. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
MONALEESA-3 was a randomized, parallel-group, quadruple-masked phase 3 treatment trial enrolling 726 participants with advanced breast cancer. The registry identifies progression-free survival per investigator assessment as the primary endpoint and reports a superiority analysis comparing ribociclib plus fulvestrant with placebo plus fulvestrant.
| Feature | MONALEESA-3 |
|---|---|
| Trial name | MONALEESA-3 |
| ClinicalTrials.gov identifier | NCT02422615 |
| Brief title | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. |
| Phase | Phase 3 |
| Status | Completed |
| Condition | Advanced Breast Cancer |
| Enrollment | 726 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Quadruple |
| Primary purpose | Treatment |
| Lead sponsor | Novartis Pharmaceuticals |
| Sponsor type | Industry |
| Start | June 9, 2015 |
| Primary completion | November 3, 2017 |
2. Clinical Question
The central statistical question was whether treatment with ribociclib plus fulvestrant produced a superior progression-free survival outcome compared with placebo plus fulvestrant in the randomized trial population with advanced breast cancer.
Population
Men and postmenopausal women with advanced breast cancer, as specified by the trial's brief title.
Intervention
Ribociclib plus fulvestrant.
Comparator
Placebo plus fulvestrant.
Primary question
Does ribociclib plus fulvestrant improve investigator-assessed progression-free survival relative to placebo plus fulvestrant?
3. Trial Design
Ribociclib + Fulvestrant
- Ribociclib
- Fulvestrant
- Serious adverse events reported for 179 of 483 at-risk participants in the on-treatment safety data
Placebo + Fulvestrant
- Placebo
- Fulvestrant
- Serious adverse events reported for 51 of 241 at-risk participants in the on-treatment safety data
The ClinicalTrials.gov record does not provide treatment dosing schedules, treatment-cycle details, stratification factors, randomization ratio, crossover rules, interim-analysis specifications, non-inferiority margins, or a factorial component. Those features are therefore not reconstructed here.
4. Endpoints
| Endpoint | Registry definition / time frame | Statistical role |
|---|---|---|
| Progression Free Survival (PFS) Per Investigator Assessment | From randomization to first documented progression or death, assessed up to approximately 26 months. | Primary endpoint |
| Overall Survival (OS) | From randomization to death, assessed up to approximately 46 months. | Secondary endpoint |
| Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) | From randomization to first documented progression or death, assessed up to approximately 26 months. | Secondary endpoint |
How the primary PFS endpoint was defined
The registry defines PFS as the period starting from the date of randomization to the date of the first documented progression or death caused by any reason. When a patient did not experience an event, PFS was censored at the date of the last adequate tumor assessment. Clinical deterioration without objective radiological evidence was not considered documented disease progression.
This definition makes PFS a classic time-to-event endpoint. The analysis therefore needs to account for both the event time and the fact that some participants may remain event-free when follow-up ends.
5. Analysis Populations
| Analysis population | Definition / role |
|---|---|
| Full Analysis Set (FAS) | All randomized patients or participants, as specified in the posted efficacy analyses. |
| Primary PFS analysis | FAS including all randomized patients. |
| Secondary OS analysis | FAS including all randomized participants. |
| Secondary BIRC PFS analysis | FAS including all randomized participants. |
The use of the full analysis set for the posted efficacy analyses preserves the randomized treatment assignment as the basis of comparison. This is closely related to the intention-to-treat principle: the comparison is anchored to how participants were randomized rather than being restricted to those who completed treatment.
6. Primary Result: Investigator-Assessed Progression-Free Survival
The primary endpoint was investigator-assessed PFS from randomization to first documented progression or death. The registry reports a formal superiority analysis using a log-rank test, with a Cox proportional-hazards effect measure.
Hazard ratio for progression or death
95% CI: 0.480–0.732 · P = 0.00000041
Analysis population: Full Analysis Set including all randomized patients.
| Primary PFS analysis | Reported value |
|---|---|
| Comparison | Ribociclib + Fulvestrant vs Placebo + Fulvestrant |
| Endpoint | Progression Free Survival (PFS) Per Investigator Assessment |
| Time frame | From randomization to first documented progression or death, assessed up to approximately 26 months |
| Analysis population | Full Analysis Set including all randomized patients |
| Statistical test | Log-rank test |
| Effect measure | Cox proportional-hazards hazard ratio |
| Hazard ratio | 0.593 |
| 95% confidence interval | 0.480–0.732 |
| P-value | 0.00000041 |
| Hypothesis type | Superiority |
A hazard ratio of 0.593 means that, under the Cox proportional-hazards model, the estimated instantaneous rate of progression or death in the ribociclib-plus-fulvestrant group was approximately 59.3% of the corresponding rate in the placebo-plus-fulvestrant group. Expressed as a simple relative interpretation, 1 − 0.593 = 0.407, so the estimate corresponds to an approximately 40.7% lower estimated hazard of progression or death.
The HR does not mean that 59.3% of participants avoided progression, that 40.7% of participants were cured, or that every participant experienced exactly a 40.7% reduction in risk. It is a relative time-to-event measure based on the fitted model.
The 95% confidence interval of 0.480–0.732 describes the uncertainty around the estimated hazard ratio under the statistical model and sampling framework. It is not a range containing the individual treatment effects experienced by patients.
The very small P-value of 0.00000041 addresses evidence against the null hypothesis under the specified statistical testing framework. It does not measure the magnitude of the treatment effect. Effect size is conveyed by the hazard ratio, while precision is conveyed by the confidence interval.
Because the effect measure is a Cox proportional-hazards hazard ratio, interpretation also depends on the proportional-hazards model being a reasonable description of the relative hazard over the relevant follow-up. The ClinicalTrials.gov record does not report diagnostics for that assumption.
7. Secondary Result: Overall Survival
Overall survival was registered as a secondary time-to-event endpoint, defined over the interval from randomization to death and assessed up to approximately 46 months. The posted analysis used the full analysis set and compared ribociclib plus fulvestrant with placebo plus fulvestrant using a log-rank test and a Cox proportional-hazards effect measure.
Hazard ratio for death
95% CI: 0.568–0.924 · P = 0.00455
Analysis population: Full Analysis Set including all randomized participants.
| Secondary OS analysis | Reported value |
|---|---|
| Comparison | Ribociclib + Fulvestrant vs Placebo + Fulvestrant |
| Endpoint | Overall Survival (OS) |
| Time frame | From randomization to death, assessed up to approximately 46 months |
| Analysis population | FAS including all randomized participants |
| Statistical test | Log-rank test |
| Effect measure | Cox proportional-hazards hazard ratio |
| Hazard ratio | 0.724 |
| 95% confidence interval | 0.568–0.924 |
| P-value | 0.00455 |
| Hypothesis type | Superiority |
A hazard ratio of 0.724 means that the estimated instantaneous rate of death under the fitted Cox model was approximately 72.4% in the ribociclib-plus-fulvestrant group relative to the placebo-plus-fulvestrant group. As a simple derived interpretation, this corresponds to an approximately 27.6% lower estimated hazard of death.
Again, the hazard ratio is not a probability and does not say that 27.6% of participants benefited or that an individual patient's mortality risk was reduced by exactly 27.6%.
The 95% CI of 0.568–0.924 quantifies uncertainty around the estimated relative hazard. Because the interval is below 1, the reported estimate is directionally consistent with a lower estimated hazard in the ribociclib-plus-fulvestrant group.
The P-value of 0.00455 measures evidence against the relevant null hypothesis under the reported analysis. It should not be interpreted as a probability that the null hypothesis is true, nor as a measure of clinical importance.
As with the primary PFS result, the Cox-model interpretation relies on the proportional-hazards framework. The ClinicalTrials.gov record does not report a formal assessment of that assumption.
8. Secondary Result: BIRC-Assessed Progression-Free Survival
A second PFS analysis used assessment by a Blinded Independent Review Committee (BIRC). The registry reports the endpoint as progression-free survival from randomization to first documented progression or death, assessed up to approximately 26 months.
Hazard ratio for progression or death
95% CI: 0.345–0.703
Analysis population: Full Analysis Set including all randomized participants.
| Secondary BIRC PFS analysis | Reported value |
|---|---|
| Comparison | Ribociclib + Fulvestrant vs Placebo + Fulvestrant |
| Endpoint | Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) |
| Time frame | From randomization to first documented progression or death, assessed up to approximately 26 months |
| Analysis population | FAS including all randomized participants |
| Statistical method | Not reported in the ClinicalTrials.gov record |
| Effect measure | Cox proportional-hazards hazard ratio |
| Hazard ratio | 0.492 |
| 95% confidence interval | 0.345–0.703 |
| P-value | Not reported in the ClinicalTrials.gov record |
| Hypothesis type | Superiority |
The BIRC PFS hazard ratio of 0.492 corresponds to an estimated hazard approximately 49.2% as large in the ribociclib-plus-fulvestrant group as in the placebo-plus-fulvestrant group. As a direct derived interpretation, that is approximately a 50.8% lower estimated hazard of progression or death.
The 95% CI of 0.345–0.703 describes the precision of this estimate under the reported model. The ClinicalTrials.gov record does not report a P-value for this analysis, so no formal P-value interpretation should be added to the numerical result.
The absence of a reported statistical method in the ClinicalTrials.gov record is itself important. Although the effect measure is identified as a Cox proportional-hazards hazard ratio, the ClinicalTrials.gov record does not specify the formal comparison procedure for this BIRC analysis.
9. Comparing the Three Reported Time-to-Event Analyses
| Endpoint | Assessment | HR | 95% CI | P-value | Method reported |
|---|---|---|---|---|---|
| Primary PFS | Investigator assessment | 0.593 | 0.480–0.732 | 0.00000041 | Log-rank + Cox proportional-hazards effect measure |
| Secondary OS | Overall survival | 0.724 | 0.568–0.924 | 0.00455 | Log-rank + Cox proportional-hazards effect measure |
| Secondary PFS | BIRC assessment | 0.492 | 0.345–0.703 | Not reported | Not reported in the ClinicalTrials.gov record |
The three estimates should not be treated as interchangeable measurements. They concern different endpoints or assessment procedures. Investigator-assessed PFS is the registered primary endpoint; OS measures death rather than progression; and BIRC PFS uses an independent review process. The estimates therefore answer related but distinct statistical questions.
10. Statistical Methodology
Time-to-event analysis
All three posted statistical analyses concern time-to-event endpoints. In this setting, the outcome is not simply whether an event occurred, but when the event occurred. Participants who have not experienced the event by the end of their observed follow-up can contribute information up to the point at which they are censored.
The survival function represents the probability that the event time T exceeds time t. PFS and OS are both examples of time-to-event outcomes, but their event definitions differ.
Kaplan-Meier estimation
A Kaplan-Meier estimator is the standard descriptive approach for displaying and estimating a time-to-event distribution in the presence of right censoring. The ClinicalTrials.gov record identifies the endpoints as time-to-event outcomes but do not explicitly state that Kaplan-Meier estimation was used in the posted statistical-analysis records.
Here di represents events at time ti, while ni represents the number at risk immediately before that time.
Log-rank test
The primary PFS and secondary OS analyses were reported as using a log-rank test. The log-rank test compares the observed and expected numbers of events between treatment groups over follow-up. It is designed for time-to-event comparisons and naturally incorporates censored observations.
Cox proportional-hazards model
The reported effect measure for the primary PFS, OS, and BIRC PFS analyses was a Cox proportional-hazards hazard ratio. The Cox model expresses the treatment effect through a relative hazard while allowing the baseline hazard to remain unspecified.
An HR below 1 indicates a lower estimated instantaneous event rate in the treatment group relative to the comparator under the fitted model. It is not an absolute risk difference.
Full Analysis Set and intention-to-treat principle
The posted efficacy analyses use the Full Analysis Set including all randomized participants. This is important because randomized comparisons are most directly connected to the treatment assignment generated by randomization. Excluding participants after randomization because of treatment discontinuation or other post-randomization events can alter the meaning of the comparison.
Superiority testing
The statistical analyses identify superiority as the hypothesis type. This differs from a non-inferiority design: the goal is not to show that the treatment is sufficiently close to control, but to test whether the treatment comparison provides evidence of a favorable difference under the prespecified superiority framework.
11. Statistical Methods Explained
Why is a log-rank test appropriate for PFS and OS?
PFS and OS are time-to-event outcomes. A simple comparison of proportions at a single time point would discard much of the information about when events occurred and how long participants were followed. The log-rank test uses event timing across follow-up and accounts for censoring.
What does a hazard ratio of 0.593 mean?
A hazard ratio of 0.593 means that the estimated instantaneous rate of progression or death under the fitted model is about 59.3% of the comparator rate. The complementary quantity, 1 − 0.593, is 0.407, giving an approximately 40.7% lower estimated hazard. This is a relative model-based statement, not a statement that 40.7% of patients avoided progression.
Why does the confidence interval matter?
The point estimate alone does not communicate how precisely the treatment effect has been estimated. The 95% confidence interval of 0.480–0.732 for the primary PFS hazard ratio describes uncertainty around the estimate. A narrower interval would indicate greater precision than a wider interval, all else being equal.
Why doesn't the P-value measure effect size?
The P-value is a measure of compatibility between the observed data and the null hypothesis under the specified statistical model and testing procedure. It does not quantify how large the treatment effect is. The hazard ratio describes relative effect size, while the confidence interval communicates uncertainty around that estimate.
Why can PFS and OS have different hazard ratios?
PFS and OS have different event definitions. PFS counts the first documented progression or death, whereas OS is defined from randomization to death. Because they measure different events, their treatment-effect estimates need not be numerically equal or have the same precision.
What does the BIRC result add?
The BIRC analysis evaluates PFS using a blinded independent review committee rather than investigator assessment. Comparing the reported investigator-assessed and BIRC hazard ratios can provide a descriptive view of how the estimated relative effect changes with assessment method. It should not, however, be interpreted as two independent primary tests.
12. Why the Full Analysis Set Matters
The primary PFS analysis was conducted in the Full Analysis Set including all randomized patients. This is statistically important because randomization establishes the initial comparability of treatment groups. An analysis based on the randomized population maintains that treatment-assignment framework.
Preserves randomization
Participants remain associated with the treatment strategy to which they were randomized for the efficacy comparison.
Avoids post-randomization selection
Restricting efficacy analyses only to participants who remain on treatment can introduce selection related to events occurring after randomization.
Matches the posted analysis
The registry explicitly identifies the Full Analysis Set as the analysis population for the posted primary PFS result.
Interpretation remains causal in design
The randomized comparison is anchored to treatment assignment rather than treatment adherence alone.
13. Confidence Intervals in the MONALEESA-3 Results
The three posted hazard-ratio analyses illustrate why confidence intervals should accompany point estimates.
| Analysis | HR | 95% CI | What the interval communicates |
|---|---|---|---|
| Primary investigator-assessed PFS | 0.593 | 0.480–0.732 | Uncertainty around the estimated relative hazard of progression or death. |
| Secondary OS | 0.724 | 0.568–0.924 | Uncertainty around the estimated relative hazard of death. |
| Secondary BIRC PFS | 0.492 | 0.345–0.703 | Uncertainty around the estimated relative hazard of progression or death under BIRC assessment. |
All three reported intervals lie below 1.00. That descriptive feature is consistent with hazard estimates below 1 for each comparison. The strength of formal inference, however, depends on the endpoint's role, prespecified testing framework, analysis method, and whether multiplicity was controlled.
14. Safety Results
The ClinicalTrials.gov record reports serious adverse events by treatment arm for the on-treatment safety data.
| Safety measure | Affected / at risk |
|---|---|
| Ribociclib + Fulvestrant, on-treatment | 179 / 483 |
| Placebo + Fulvestrant, on-treatment | 51 / 241 |
| Crossover to Ribociclib + Fulvestrant | 1 / 3 |
The ClinicalTrials.gov record reports serious adverse events as affected participants over an at-risk population. They do not provide a formal between-arm statistical test for serious adverse events, a confidence interval, or a treatment-effect estimate for this safety endpoint. Accordingly, these counts should not be converted into a formal comparative inference that the registry data do not report.
15. Design Features Not Reported in the Supplied Statistical Record
The registry-reported MONALEESA-3 data support several important statistical design observations, but they do not support reconstruction of every design feature that might appear in a full protocol or statistical analysis plan.
| Design topic | What the ClinicalTrials.gov record supports |
|---|---|
| Randomization | Yes. The trial is identified as randomized. |
| Blinding | Yes. Masking is identified as quadruple. |
| Parallel design | Yes. The design model is parallel. |
| Superiority | Yes. The posted analyses identify superiority as the hypothesis type. |
| Non-inferiority margin | Not reported in the ClinicalTrials.gov record and not applicable to the stated superiority hypothesis. |
| Factorial design | Not reported; the registry-reported design model is parallel with two arms. |
| Crossover | A crossover safety record is present in the registry-reported serious-adverse-event data, but no broader crossover design rule is provided. |
| Interim analysis | Not reported in the registry-reported statistical data. |
| Missing-data / imputation method | Not reported in the ClinicalTrials.gov record. |
| Stratification factors | Not reported in the ClinicalTrials.gov record. |
| Bayesian methods | Not reported. |
This distinction matters because a statistical analysis page should not infer protocol details merely because they are common in phase 3 trials. The ClinicalTrials.gov record supports the methods and interpretations stated here; unsupported design assumptions are deliberately excluded.
16. Understanding the Primary PFS Result
The primary hazard ratio of 0.593 indicates a lower estimated instantaneous rate of progression or death in the ribociclib-plus-fulvestrant group relative to the placebo-plus-fulvestrant group under the Cox model.
The directly derived complement of the HR, 1 − 0.593 = 0.407, corresponds to an approximately 40.7% lower estimated hazard. This is a relative model-based interpretation and should not be converted into an absolute percentage of patients who benefited.
The 95% CI of 0.480–0.732 indicates that the point estimate is not known exactly. It provides a statistical interval for the treatment-effect estimate rather than a prediction interval for individual patients.
The reported P = 0.00000041 provides very strong statistical evidence against the null hypothesis under the specified log-rank testing framework. The P-value does not itself quantify treatment magnitude or clinical importance.
17. Interpreting the OS Result Separately
The OS hazard ratio of 0.724 should be read independently from the PFS hazard ratio. OS is a different endpoint with death as the event, whereas PFS includes progression or death.
| Question | Primary PFS | Secondary OS |
|---|---|---|
| What is the event? | First documented progression or death | Death |
| Time origin | Randomization | Randomization |
| Reported HR | 0.593 | 0.724 |
| 95% CI | 0.480–0.732 | 0.568–0.924 |
| P-value | 0.00000041 | 0.00455 |
| Statistical test | Log-rank | Log-rank |
The difference between the two HR estimates does not by itself establish that one endpoint is more important or that the treatment effect truly differs between progression and death. They measure different events and therefore should be interpreted according to their separate clinical and statistical definitions.
18. Investigator Assessment Versus BIRC Assessment
The registry contains both investigator-assessed PFS and BIRC-assessed PFS. This provides a useful statistical teaching point: an endpoint can be defined identically in terms of its event structure while differing in who determines whether progression has occurred.
Investigator-assessed PFS
Primary endpoint. Hazard ratio 0.593 with a 95% CI of 0.480–0.732 and P = 0.00000041.
BIRC-assessed PFS
Secondary endpoint. Hazard ratio 0.492 with a 95% CI of 0.345–0.703; no P-value is reported in the registry-reported statistical record.
The BIRC estimate is numerically lower than the investigator-assessed estimate, but the two confidence intervals overlap. Without a formal statistical comparison of the two estimates, the numerical difference should not be interpreted as evidence that independent review produces a systematically different treatment effect.
19. Statistical Concepts in MONALEESA-3
MONALEESA-3 brings several core clinical-trial statistical concepts together in a single randomized time-to-event framework.
| Concept | How it appears in this trial |
|---|---|
| Randomization | The trial uses randomized allocation. |
| Blinding | Masking is identified as quadruple. |
| Parallel design | The design model is parallel with two arms. |
| Full Analysis Set | Primary and secondary efficacy analyses use all randomized participants in the FAS. |
| Time-to-event endpoints | PFS and OS are analyzed as time-to-event outcomes. |
| Log-rank test | Reported for the primary PFS and secondary OS analyses. |
| Hazard ratio | Used as the effect measure for all three posted statistical analyses. |
| Cox proportional hazards | Reported as the effect-measure framework. |
| Confidence intervals | 95% two-sided confidence intervals are reported for all three posted hazard-ratio estimates. |
| Superiority testing | The primary and secondary formal analyses identify superiority as the hypothesis type. |
| Independent review | BIRC-assessed PFS provides a separately assessed secondary endpoint. |
20. Important Limitations and Interpretation Issues
- Hazard-ratio interpretation: a Cox hazard ratio is a model-based relative measure and is not equivalent to an absolute risk difference or a probability of benefit.
- Proportional-hazards assumption: interpretation of a single Cox HR depends on the proportional-hazards framework. The ClinicalTrials.gov record does not report a formal diagnostic assessment.
- Censoring: PFS explicitly uses censoring for participants without an event at the date of the last adequate tumor assessment. Censoring assumptions therefore matter to the analysis.
- Different endpoints: PFS and OS measure different events and should not be treated as interchangeable outcomes.
- Assessment method: investigator-assessed and BIRC-assessed PFS are related but distinct analyses. A numerical difference between their HRs is not, by itself, evidence of heterogeneity.
- Multiplicity: the ClinicalTrials.gov record identifies one primary endpoint and multiple posted statistical analyses, but they do not provide the complete multiplicity-control strategy. P-values should therefore be interpreted according to the role of each endpoint rather than pooled indiscriminately.
- Unreported methods: the BIRC PFS record does not provide a normalized statistical method or P-value in the ClinicalTrials.gov record. The absence of those fields should not be filled by inference.
- Safety populations: the registry-reported serious-adverse-event figures are on-treatment data and should not be interpreted as if they were the same analysis population used for the primary efficacy endpoint.
- Limited registry detail: the ClinicalTrials.gov record does not provide baseline characteristics, median PFS, median OS, subgroup analyses, or a full statistical analysis plan.
21. Why This Trial Matters Statistically
MONALEESA-3 is a useful teaching example because it shows how a randomized phase 3 trial can generate multiple related time-to-event analyses without treating every numerical result as the same statistical question.
Primary endpoint discipline
The primary registered endpoint is investigator-assessed PFS, so the 0.593 hazard ratio and its 95% CI and P-value form the central confirmatory result in the ClinicalTrials.gov record.
Relative effect versus precision
The HR communicates relative treatment effect, while the confidence interval communicates uncertainty around that estimate.
Endpoint-specific inference
OS and PFS are both time-to-event outcomes but have different event definitions, so their hazard ratios answer different questions.
Independent assessment
The BIRC PFS analysis demonstrates why endpoint assessment procedures should be considered when interpreting a trial's statistical evidence.
22. A Practical Reading Strategy for the MONALEESA-3 Results
- Start with the endpoint definition. Determine exactly what constitutes an event and when follow-up begins.
- Identify the analysis population. Here, the posted efficacy analyses use the Full Analysis Set including randomized participants.
- Identify the comparison. The reported comparisons are ribociclib plus fulvestrant versus placebo plus fulvestrant.
- Read the hazard ratio. A value below 1 indicates a lower estimated event hazard in the ribociclib-containing group under the Cox model.
- Read the confidence interval. This indicates the statistical precision of the estimated relative effect.
- Read the P-value separately. The P-value addresses evidence against the null hypothesis; it does not quantify effect size.
- Check the endpoint's role. The primary PFS result should not be treated as statistically interchangeable with secondary OS or BIRC PFS analyses.
- Check what is not reported. Missing design details should not be reconstructed from assumptions about how similar phase 3 trials are usually analyzed.
23. Related Tutorials
Learn more about the methods used in this trial:
24. Related Calculators
25. Sources
- ClinicalTrials.gov: MONALEESA-3, NCT02422615.
- Linked publication: PubMed PMID 42334791.
- Linked publication: PubMed PMID 39826197.
- Linked publication: PubMed PMID 37673211.
- Linked publication: PubMed PMID 37653397.
- Linked publication: PubMed PMID 36800111.
Continue learning through Clinical Biostats
Connect the trial's endpoints and statistical methods to deeper tutorials and practical statistical tools.
26. Record Summary
MONALEESA-3 provides a clear example of randomized clinical-trial analysis centered on time-to-event outcomes. The trial enrolled 726 participants in a randomized, parallel, quadruple-masked phase 3 design. Its registered primary endpoint was investigator-assessed progression-free survival, analyzed in the Full Analysis Set using a log-rank test with a Cox proportional-hazards hazard ratio. The reported primary estimate was 0.593, with a two-sided 95% confidence interval of 0.480–0.732 and a P-value of 0.00000041.
The posted secondary analyses extend the statistical picture without making the endpoints interchangeable. Overall survival produced a hazard ratio of 0.724 with a 95% confidence interval of 0.568–0.924 and P = 0.00455. BIRC-assessed PFS produced a hazard ratio of 0.492 with a 95% confidence interval of 0.345–0.703, without a P-value reported in the ClinicalTrials.gov record.
The most important statistical lesson is that these numbers should be read together with their endpoint definitions, analysis populations, statistical methods, confidence intervals, and hypothesis-testing roles. A hazard ratio describes a relative time-to-event effect; it does not replace absolute outcomes, does not describe individual treatment benefit, and does not by itself establish every aspect of clinical importance.